Influenza virus vaccine quadrivalent - Shanghai Institute Of Biological Products
Alternative Names: Quadrivalent influenza virus split vaccine - Shanghai Institute Of Biological ProductsLatest Information Update: 07 Mar 2025
At a glance
- Originator Shanghai Institute of Biological Products
- Class Influenza virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 31 Dec 2024 Shanghai Institute Of Biological Products completes phase I trial in Influenza virus infections (Prevention, In infants, In children, In adolescents, In adults, In the elderly) in China (Parenteral) (NCT06342349)
- 13 Oct 2024 Phase-I clinical trials in Influenza virus infections (In children, In adolescents, In adults, In the elderly) in China (Parenteral) (NCT06622590)
- 30 Mar 2024 Phase-I clinical trials in Influenza virus infections (Prevention, In infants, In children, In adolescents, In adults, In the elderly) in China (Parenteral) (NCT06342349)